DMK Pharmaceuticals Corporation
DMKPQ
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 3.62M | 5.12M | 5.15M | 4.85M | 1.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.62M | 5.12M | 5.15M | 4.85M | 1.54M |
| Cost of Revenue | 4.97M | 6.28M | 6.61M | 6.28M | 5.47M |
| Gross Profit | -1.35M | -1.16M | -1.46M | -1.43M | -3.92M |
| SG&A Expenses | 12.97M | 13.07M | 14.65M | 13.25M | 12.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.90M | 23.88M | 28.72M | 29.91M | 30.17M |
| Operating Income | -17.28M | -18.76M | -23.57M | -25.06M | -28.63M |
| Income Before Tax | -21.16M | -23.69M | -25.02M | -26.20M | -30.61M |
| Income Tax Expenses | 2.00K | 2.00K | 2.00K | 2.00K | 800.00 |
| Earnings from Continuing Operations | -21.16 | -23.69 | -25.02 | -26.20 | -30.61 |
| Earnings from Discontinued Operations | -1.08M | -1.55M | -42.30K | -278.90K | -1.32M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.23M | -25.24M | -25.07M | -26.48M | -31.92M |
| EBIT | -17.28M | -18.76M | -23.57M | -25.06M | -28.63M |
| EBITDA | -16.65M | -17.79M | -22.32M | -23.58M | -27.16M |
| EPS Basic | -9.25 | -11.10 | -11.62 | -12.37 | -14.94 |
| Normalized Basic EPS | -3.64 | -4.74 | -7.42 | -7.28 | -8.43 |
| EPS Diluted | -9.32 | -11.18 | -11.70 | -12.51 | -15.07 |
| Normalized Diluted EPS | -3.64 | -4.74 | -7.42 | -7.28 | -8.43 |
| Average Basic Shares Outstanding | 13.96M | 9.04M | 8.61M | 8.56M | 8.55M |
| Average Diluted Shares Outstanding | 13.96M | 9.04M | 8.61M | 8.56M | 8.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |